(Q43228476)

16 November 2017

title

A randomized controlled trial of plasma real-time PCR and antigenemia assay for monitoring CMV infection after unrelated BMT. (English)

1 reference

16 November 2017

Y Kanda

1

1 reference

16 November 2017

T Yamashita

2

1 reference

16 November 2017

T Mori

3

1 reference

16 November 2017

T Ito

4

1 reference

16 November 2017

K Tajika

5

1 reference

16 November 2017

S Mori

6

1 reference

16 November 2017

T Sakura

7

1 reference

16 November 2017

M Hara

8

1 reference

16 November 2017

K Mitani

9

1 reference

16 November 2017

M Kurokawa

10

1 reference

16 November 2017

K Akashi

11

1 reference

16 November 2017

M Harada

12

1 reference

16 November 2017

language of work or name

English

0 references

publication date

7 December 2009

1 reference

Bone Marrow Transplantation

16 November 2017

published in

1 reference

16 November 2017

volume

45

1 reference

16 November 2017

issue

8

1 reference

16 November 2017

page(s)

1325-1332

1 reference

How we treat cytomegalovirus in hematopoietic cell transplant recipients

16 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.337

Management of CMV infections: recommendations from the infectious diseases working party of the EBMT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.337

Pre-emptive therapy against cytomegalovirus (CMV) disease guided by CMV antigenemia assay after allogeneic hematopoietic stem cell transplantation: a single-center experience in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.337

Response-oriented preemptive therapy against cytomegalovirus disease with low-dose ganciclovir: a prospective evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.337

Dose-adjusted preemptive therapy for cytomegalovirus disease based on real-time polymerase chain reaction after allogeneic hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.337

Use of a DNAemia cut-off for monitoring human cytomegalovirus infection reduces the number of preemptively treated children and young adults receiving hematopoietic stem-cell transplantation compared with qualitative pp65 antigenemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.337

Suspected delayed immune recovery against cytomegalovirus after reduced-intensity stem cell transplantation using anti-thymocyte globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.337

Monitoring cytomegalovirus infection by antigenemia assay and two distinct plasma real-time PCR methods after hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.337

Pharmacokinetics of ganciclovir in haematopoietic stem cell transplantation recipients with or without renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.337

Clinical features of late cytomegalovirus infection after hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.337

Clinical significance of cytomegalovirus (CMV) antigenemia in the prediction and diagnosis of CMV gastrointestinal disease after allogeneic hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.337

Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.337

7 January 2021

Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.337

7 January 2021

Plasma polymerase chain reaction for cytomegalovirus DNA after allogeneic marrow transplantation: comparison with polymerase chain reaction using peripheral blood leukocytes, pp65 antigenemia, and viral culture

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.337

7 January 2021

Time course analysis of semi-quantitative PCR and antigenaemia assay for prevention of cytomegalovirus disease after bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.337

7 January 2021

Validation of a DNAemia cutoff for preemptive therapy of cytomegalovirus infection in adult hematopoietic stem cell transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.337

7 January 2021

Once daily ganciclovir as initial pre-emptive therapy delayed until threshold CMV load > or =10000 copies/ml: a safe and effective strategy for allogeneic stem cell transplant patients

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.337

7 January 2021

Frequent detection of rising cytomegalovirus antigenemia after allogeneic stem cell transplantation following a regimen containing antithymocyte globulin

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.337

7 January 2021

Factors influencing detection of quantitative cytomegalovirus antigenemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.337

7 January 2021

A three-center European external quality control study of PCR for detection of cytomegalovirus DNA in blood

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.337

7 January 2021

Standardization of the human cytomegalovirus antigenemia assay by means of in vitro-generated pp65-positive peripheral blood polymorphonuclear leukocytes

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.337

7 January 2021

Towards standardization of the human cytomegalovirus antigenemia assay

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.337

7 January 2021

Identifiers

DOI

10.1038/BMT.2009.337

1 reference

Dimensions Publication ID

16 November 2017

1006657072

0 references

1 reference